KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Other Non-Current Liabilities (2018 - 2025)

Vir Biotechnology's Other Non-Current Liabilities history spans 8 years, with the latest figure at $21.6 million for Q4 2025.

  • On a quarterly basis, Other Non-Current Liabilities rose 48.03% to $21.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $21.6 million, a 48.03% increase, with the full-year FY2025 number at $21.6 million, up 48.03% from a year prior.
  • Other Non-Current Liabilities hit $21.6 million in Q4 2025 for Vir Biotechnology, up from $13.3 million in the prior quarter.
  • Over the last five years, Other Non-Current Liabilities for VIR hit a ceiling of $46.0 million in Q1 2021 and a floor of $3.9 million in Q2 2021.
  • Historically, Other Non-Current Liabilities has averaged $20.0 million across 5 years, with a median of $18.3 million in 2021.
  • The widest YoY moves for Other Non-Current Liabilities: up 1464.79% in 2021, down 87.44% in 2021.
  • Tracing VIR's Other Non-Current Liabilities over 5 years: stood at $22.8 million in 2021, then plummeted by 51.3% to $11.1 million in 2022, then soared by 42.01% to $15.8 million in 2023, then decreased by 7.65% to $14.6 million in 2024, then skyrocketed by 48.03% to $21.6 million in 2025.
  • Business Quant data shows Other Non-Current Liabilities for VIR at $21.6 million in Q4 2025, $13.3 million in Q3 2025, and $33.6 million in Q2 2025.